Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice
Neuropsychopharmacology · 2024
DOI: 10.1038/s41386-023-01774-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology, 2024. Verfasst von Zhengjiang Qian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese A…. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases, Cysteine Endopeptidases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disease with cognitive dysfunction as its major clinical symptom. However, there is no disease-modifying small molecular medicine to effectively slow down progression of the disease. Here, we show an optimized asparagine endopeptidase (AEP, also known as δ-secretase) inhibitor, #11 A, that displays an orderly in vivo pharmacokinetics/pharmacodynamics (PK/PD) relationship and robustly attenuates AD pathologies in a sporadic AD mouse model. #11 A is brain permeable with great oral bioavailability. It blocks AEP cleavage of APP and Tau dose-dependently, and significantly decreases Aβ40 and Aβ42 and p-Tau levels in APP/PS1 and Tau P301S mice after oral administration. Notably, #11 A strongly inhibits AEP and prevents mouse APP and Tau fragmentation by AEP, leading to reduction of mouse Aβ42 (mAβ42), mAβ40 and mouse p-Tau181 levels in Thy1-ApoE4/C/EBPβ transgenic mice in a dose-dependent manner. Repeated oral administration of #11 A substantially decreases mAβ aggregation as validated by Aβ PET assay, Tau pathology, neurodegeneration and brain volume reduction, resulting in alleviation of cognitive impairment. Therefore, our results support that #11 A is a disease-modifying preclinical candidate for pharmacologically treating AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China.
- Shenzhen Institute of Advanced Technology, University of Chinese Academy of Science, Shenzhen, Guangdong, 518055, China.
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
- School of Medicine, Tongji University, Shanghai, 200092, China.
- Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. qian.luo@siat.ac.cn.
- Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China. kq.ye@siat.ac.…
ORCID-Profile: Keqiang Ye
Zitieren
APA
Qian, Z., Li, B., Meng, X., Liao, J., Wang, G., Li, Y., Luo, Q., & Ye, K. (2024). Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01774-2
Vancouver
Qian Z, Li B, Meng X, Liao J, Wang G, Li Y, et al. Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice. Neuropsychopharmacology. 2024. doi:10.1038/s41386-023-01774-2
BibTeX
@article{Qian2024,
author = {Qian, Zhengjiang and Li, Bowei and Meng, Xin and Liao, Jianming and Wang, Guangxing and Li, Yanjiao and Luo, Qian and Ye, Keqiang},
title = {Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice},
journal = {Neuropsychopharmacology},
year = {2024},
doi = {10.1038/s41386-023-01774-2}
}
EUVIMED